BidaskClub upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a sell rating to a hold rating in a research report released on Monday.

Several other brokerages have also recently issued reports on ILMN. Deutsche Bank AG set a $175.00 target price on Illumina and gave the company a hold rating in a report on Friday, July 28th. Vetr cut Illumina from a strong-buy rating to a buy rating and set a $193.40 target price for the company. in a report on Tuesday, April 11th. Morgan Stanley restated an underweight rating and issued a $122.00 target price (up from $115.00) on shares of Illumina in a report on Monday, July 10th. Bank of America Corporation upped their target price on Illumina from $175.00 to $195.00 and gave the company a buy rating in a report on Tuesday, April 11th. Finally, Barclays PLC restated a hold rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $176.63.

Illumina (ILMN) traded down 0.4264% on Monday, reaching $198.7289. 134,838 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $174.66 and a 200-day moving average price of $171.89. Illumina has a 52 week low of $119.37 and a 52 week high of $199.86. The stock has a market capitalization of $29.01 billion, a price-to-earnings ratio of 39.8734 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The company had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.86 EPS. On average, analysts predict that Illumina will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/08/illumina-inc-ilmn-upgraded-to-hold-by-bidaskclub.html.

In related news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $197.00, for a total transaction of $316,973.00. Following the completion of the transaction, the senior vice president now directly owns 9,037 shares in the company, valued at approximately $1,780,289. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total value of $3,604,800.00. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at $97,181,082.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,639 shares of company stock valued at $24,037,438. Company insiders own 1.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Advocacy Wealth Management Services LLC purchased a new position in shares of Illumina during the first quarter worth approximately $102,000. Gemmer Asset Management LLC boosted its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC purchased a new position in shares of Illumina during the first quarter worth approximately $117,000. Penserra Capital Management LLC boosted its position in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the period. Finally, Paradigm Asset Management Co. LLC boosted its position in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the period. Institutional investors own 93.81% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.